EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Impact of Proton Pump Inhibitor Use on Progression-Free and Overall Survival in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy: A Systematic Review and Meta-Analysis of Recent Studies

Einfluss von Protonenpumpenhemmer-Anwendung auf progressionsfreies und Gesamtüberleben bei Krebspatient:innen unter Immun-Checkpoint-Inhibitor-Therapie: systematische Übersicht und Metaanalyse aktueller Studien

Giuliana Ciappina iD, Alessandro Ottaiano iD, Mariachiara Santorsola, Emanuela Esposito iD, Fabiola De Luca iD, Carlotta Giorgi iD, Concetta Zito iD, Anna Paola Capra iD, Patrizia Carroccio iD, Nicola Maurea iD, Vincenzo Quagliariello, Irene Campo und 5 weitere

Cancers · 03.07.2025 · 17 (13) · 2228

DOI: 10.3390/cancers17132228 ↗

Auf einen Blick

Sieben Studien zeigen: Unter Protonenpumpenhemmern waren PFS und OS bei Patient:innen mit soliden Tumoren unter ICIs schlechter. Für PFS war der Zusammenhang statistisch nicht klar.

Fragestellung

Welchen Zusammenhang hat die Anwendung von Protonenpumpenhemmern mit PFS und OS bei Krebspatient:innen unter ICI-Therapie?

Methode

Systematische Literaturrecherche in PubMed, Scopus und EMBASE; Studien zu PPI und PFS/OS bei soliden Tumoren unter ICIs; Synthese mit Fixed- und Random-Effects-Modellen; Bewertung mit MINORS und NOS.

Ergebnisse

7 Studien. PFS: 1.367 Teilnehmende; HR 1,12 (95 %-KI 0,90–1,34). OS: 10.420 Teilnehmende; HR 1,18 (95 %-KI 1,11–1,25).

Einschränkungen

Studien aus November 2022 bis Januar 2025; Heterogenität und Publikationsbias wurden geprüft.

Schlussfolgerung der Autor:innen

Die beobachtete Assoziation zwischen PPI-Exposition und verminderter Wirksamkeit von ICIs mit schlechterem PFS und OS ist ein potenzielles klinisches Problem und sollte prospektiv weiter untersucht werden.

Kernaussagen

  • PFS: HR 1,12 (95 %-KI 0,90–1,34)
  • OS: HR 1,18 (95 %-KI 1,11–1,25)
  • 7 eingeschlossene Studien, Fokus auf aktuelle Evidenz

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 03.07.2025. Verfasst von Giuliana Ciappina und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Sciences, Section of Experimental Medicine, University of Ferrara, 44121 Ferrara, Italy. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian National Recovery and Resilience Plan (PNRR), European Union - NextGenerationEU, Italian National Recovery and Resilience Plan (PNRR).

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The introduction of immunotherapy has significantly improved survival outcomes in many solid tumors. However, a subset of patients exhibits limited responsiveness to immune checkpoint inhibitors (ICIs). Emerging evidence indicates that the gut microbiota plays a critical role in modulating the effectiveness of immunotherapy. Consequently, the concurrent use of certain medications that disrupt microbial diversity may contribute to reduced treatment efficacy. Among the agents implicated in altering the gut microbiota are antibiotics and proton pump inhibitors (PPIs).

Methods

A systematic literature search was conducted in PubMed, Scopus, and EMBASE. Eligible studies assessed the association between PPI use and progression-free survival (PFS) and/or overall survival (OS) in patients with solid tumors receiving ICIs. They reported hazard ratios (HRs) with 95% confidence intervals (CIs). The analysis focused on studies published between November 2022 and January 2025, in continuity with prior comprehensive meta-analyses that included studies up to November 2022. This contiguity-based approach enabled a focused evaluation of recent evidence, minimizing redundancy while allowing for the detection of evolving trends in clinical practice and methodology. Data were synthesized using both fixed-effects and random-effects models and visualized via Forest plots. Study quality was assessed using the Methodological Index for Non-Randomized Studies (MINORS) and the Newcastle–Ottawa Scale (NOS). Between-study heterogeneity and publication bias were evaluated using I2 statistics and funnel plots.

Results

From a pool of over 400 screened articles between November 2022 and January 2025, seven studies met the inclusion criteria. The PFS analysis incorporated data from 1367 participants, while the OS analysis included 10,420 individuals. Use of PPIs was linked to a 12% higher risk of disease progression (HR = 1.12; 95% CI: 0.90–1.34) and an 18% increased mortality risk (HR = 1.18; 95% CI: 1.11–1.25).

Conclusions

The observed association between PPIs exposure and reduced efficacy of ICIs, as reflected in worsened PFS and OS outcomes, highlights a potential clinical concern that merits further investigation in prospective studies.

Schlagwörter

Stichwörter der Autor:innen

PPIsimmune checkpoint inhibitorsimmunotherapymicrobiotaproton-pump inhibitorssolid tumors

Autor:innen und Institutionen

  • Department of Medical Sciences, Section of Experimental Medicine, University of Ferrara, 44121 Ferrara, Italy.
  • Division of Innovative Therapies for Abdominal Metastases, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, 80131 Naples, Italy.
  • Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, 98166 Messina, Italy.
  • Laboratory for Technologies of Advanced Therapies (LTTA), Department of Morphology, Surgery and Experimental Medicine, Section of Pathology, Oncology and Experimental Biology, University of Ferrara, 48033 Ferrara, Italy.
  • Cardiology Unit, Department of Clinical and Experimental Medicine, University of Messina, 98166 Messina, Italy.
  • School of Specialization in Medical Oncology, Department of Human Pathology "G. Barresi", University of Messina, 98125 Messina, Italy.

ORCID-Profile: Giuliana Ciappina, Alessandro Ottaiano, Emanuela Esposito, Fabiola De Luca, Carlotta Giorgi, Concetta Zito, Anna Paola Capra, Patrizia Carroccio, Nicola Maurea, Maria Ilenia Passalacqua, Irene Cacciola, Massimiliano Berretta

Förderung

  • Italian National Recovery and Resilience Plan (PNRR), European Union - NextGenerationEU
  • Italian National Recovery and Resilience Plan (PNRR)

Zitieren

APA

Ciappina, G., Ottaiano, A., Santorsola, M., Esposito, E., De Luca, F., Giorgi, C., Zito, C., Capra, A. P., Carroccio, P., Maurea, N., Quagliariello, V., Campo, I., Passalacqua, M. I., Incognito, D., Cacciola, I., Consolo, P., & Berretta, M. (2025). Impact of Proton Pump Inhibitor Use on Progression-Free and Overall Survival in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy: A Systematic Review and Meta-Analysis of Recent Studies. Cancers, 17(13), 2228. https://doi.org/10.3390/cancers17132228

Vancouver

Ciappina G, Ottaiano A, Santorsola M, Esposito E, De Luca F, Giorgi C, et al. Impact of Proton Pump Inhibitor Use on Progression-Free and Overall Survival in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy: A Systematic Review and Meta-Analysis of Recent Studies. Cancers. 2025;17(13):2228. doi:10.3390/cancers17132228

BibTeX
@article{Ciappina2025,
  author = {Ciappina, Giuliana and Ottaiano, Alessandro and Santorsola, Mariachiara and Esposito, Emanuela and De Luca, Fabiola and Giorgi, Carlotta and Zito, Concetta and Capra, Anna Paola and Carroccio, Patrizia and Maurea, Nicola and Quagliariello, Vincenzo and Campo, Irene and Passalacqua, Maria Ilenia and Incognito, Dalila and Cacciola, Irene and Consolo, Pierluigi and Berretta, Massimiliano},
  title = {Impact of Proton Pump Inhibitor Use on Progression-Free and Overall Survival in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy: A Systematic Review and Meta-Analysis of Recent Studies},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {13},
  pages = {2228},
  doi = {10.3390/cancers17132228}
}
Kostenlos starten →